Why We Lose Energy and Motivation in Depression- Insight from Dr. Rezaul Hamid I Viatris CME Lecture

Why We Lose Energy and Motivation in Depression- Insight from Dr. Rezaul Hamid I Viatris CME Lecture

🧠 Energy, Motivation & Interest (EMI) in Depression | Dr. Rezaul Hamid | Viatris CME Webinar
Depression is more than sadness — it disrupts energy, motivation, and interest (EMI), the neurobiological core of purposeful life.
In this academic webinar, Dr. Rezaul Hamid, Psychiatrist and Founder-Director of Mindcare Neuro Psychiatry Research Centre (Assam), examines how dopamine, serotonin, and noradrenaline circuits explain residual symptoms, anhedonia, and recovery patterns.
This Viatris-supported CME session highlights:
• Dopaminergic dysfunction in residual symptoms
• EMI as a marker for remission and functional recovery
• Translational insights on Sertraline and other antidepressants
• The shift from symptom control to functional restoration
🎥 Professionally recorded and edited for continuing medical education.
Ideal for psychiatrists, psychologists, and mental-health clinicians seeking evidence-based understanding of depression’s circuitry and treatment advances.
The video is edited in Filmora Professional and music track Automn’s Evening taken from Filmore Copyright free archive. No copyright infringement intended
#Depression #Sertraline #Psychiatry #MentalHealth #Neuroscience #DrRezaulHamid #Mindcare #Viatris #Psychopharmacology #Anhedonia #Motivation #cme
________________________________________
📚 References (as cited)
1. Schloesser RJ et al. Neuropsychopharmacology. 2008; 33:110–133.
2. Yang R et al. BioMed Res Int. 2014; 2014:915026.
3. Kupfer DJ. J Clin Psychiatry. 1991; 52:28–34.
4. Rush JA et al. Neuropsychopharmacology. 2006; 31:1841–1853.
5. Stahl SM. Essential Psychopharmacology. Cambridge Univ Press; 2000 & 2008.
6. Thase ME et al. Int Clin Psychopharmacol. 2016; 31(6):332.
7. Grace AA. Nat Rev Neurosci. 2016; 17(8):524–532.
8. Dunlop BW, Nemeroff CB. Arch Gen Psychiatry. 2007; 64(3):327–337.
9. Kitaichi Y et al. Eur J Pharmacol. 2010; 647(1):90–96.
10. Zajecka JM. J Clin Psychiatry. 2013; 74(Suppl 2):9–13.
11. Israel JA. Pharmaceuticals. 2010; 3(8):2426–2440.
12. Kennedy SH. Dialogues Clin Neurosci. 2008; 10(3):271–277.
13. Romera I et al. BMC Psychiatry. 2013; 13:51.
14. Treadway MT, Zald DH. Neurosci Biobehav Rev. 2011; 35(3):537–555.
15. Paykel ES. Dialogues Clin Neurosci. 2008; 10(4):431–437.
16. Gelenberg AJ. APA Practice Guideline for MDD (3rd ed). 2010.
17. Kennedy SH et al. J Affect Disord. 2009; 117:S1–S2.
18. Korte SM et al. Eur J Pharmacol. 2015; 753:88–104.
19. Nestler EJ, Carlezon WA. Biol Psychiatry. 2006; 59(12):1151–1159.
20. Ciraulo DA et al. In: Pharmacotherapy of Depression. Humana Press; 2004.
21. Fabre LF et al. Biol Psychiatry. 1995; 38(9):592–602.
22. Lepine JP et al. Am J Psychiatry. 2004; 161:836–842.
23. Sanchez C et al. Int Clin Psychopharmacol. 2014; 29(4):185–196.
24. Bergeron R et al. Eur J Pharmacol. 1993; 240:319–323.
25. Boyer P et al. J Clin Pharm Ther. 2000; 25(5):363–371.
26. Keller MB et al. JAMA. 1998; 280(19):1665–1672.
27. MacQueen G et al. CNS Drug Rev. 2001; 7(1):1–24.
28. Orzechowska A et al. Med Sci Monit. 2015; 21:3643–3651.
29. Inoue T et al. Prog Neuropsychopharmacol Biol Psychiatry. 2012; 38(2):223–227.
30. Nasr S, Wendt B. Int J Psychiatry Clin Pract. 2006; 10(4):297–299.
31. Sherwood A et al. Psychosom Med. 2016; 78:602–609.
32. Krishnan KRR et al. Prog Neuropsychopharmacol Biol Psychiatry. 2001; 25:347–361.
33. Matrisciano F et al. J Psychiatr Res. 2009; 43(3):247–254.
34. Lippincott Williams & Wilkins Atlas of Anatomy. 2008.
________________________________________
#Depression #Sertraline #Psychiatry #MentalHealth #Neuroscience #DrRezaulHamid #Mindcare #Viatris #Psychopharmacology #Anhedonia #Motivation #CME #Neurobiology